Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 1 Nov 2026
Standard addition

Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism.

Lower doses of clot-busting medication worked as safely as standard doses for dangerous blood clots, potentially reducing treatment side effects.

This retrospective comparative cohort study examined Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism. In-hospital mortality did not differ significantly between groups (48% in the low-dose group vs 45% in the standard-dose group; P = .81).

What the study was

Study design
Retrospective comparative cohort study
Category
Treatment Innovation
Maturity
Exploratory
Journal
American journal of critical care : an official publication, American Association of Critical-Care Nurses

Why it surfaced

Abstract-backed retrospective comparative cohort study relevant to a high-signal out-of-watchlist clinical question; scored conservatively because full text was not assessed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.